1 / 24

Hematopoietic Stem Cell Transplantation as Immunotherapy

Hematopoietic Stem Cell Transplantation as Immunotherapy. Dr. Donna Hogge Leukemia/BMT Program of B.C. Graft Versus Host Disease Post Allogeneic Hematopoietic Stem Cell Transplant. Immunological reaction mediated by donor T lymphocytes against recipient tissues (skin, liver, gut)

stan
Download Presentation

Hematopoietic Stem Cell Transplantation as Immunotherapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hematopoietic Stem Cell Transplantation as Immunotherapy Dr. Donna Hogge Leukemia/BMT Program of B.C.

  2. Graft Versus Host Disease Post Allogeneic Hematopoietic Stem Cell Transplant • Immunological reaction mediated by donor T lymphocytes against recipient tissues (skin, liver, gut) • may occur as an ‘acute’ form within 100d of BMT or a chronic form thereafter which may persist for years • some degree of GVHD seen in ~50% sibling and >80% unrelated donor transplants in spite of prophylactic immunosuppression

  3. Graft vs Leukemia Reactions After Bone Marrow Transplantation(Horowitz et al. Blood 75:555, 1990)

  4. Can the graft vs tumor reaction operate independently of cytoreductive therapy to effect disease control?

  5. Donor Leukocyte Infusions (DLI) for Relapse post BMT • Peripheral blood mononuclear cells collected from marrow donors using a blood cell separator • In initial studies the dose was highly variable (0.1 - 15 x 108c/kg recipient weight)

  6. Graft-vs-Leukemia Effect of Donor Lymphocyte Transfusions in Marrow Grafted Patients(Kolb et al Blood 86:2041, 1995)

  7. Relationship of DLI Response to GVHD • 93% CR patients developed acute GVHD • 88% CR patients developed chronic GVHD • 13% patients who had neither acute nor chronic GVHD obtained CR • p<0.00001 Collins et al. JCO, 1997

  8. Donor Leukocyte Infusions - Vancouver Experience (1991 - 2002)

  9. Sensitivity to Graft vs Malignancy Effects • Sensitive • CML • Low grade NHL • CLL • Intermediate • AML • Intermediate grade NHL • Multiple Myeloma • Insensitive • ALL • High grade NHL • Promising (more data required) • breast cancer • renal cell carcinoma

  10. Nonmyeloablative Stem Cell Transplants (NST) • aka ‘reduced intensity conditioning transplants’ or ‘mini-transplants.’ • Rationale -  intensity of chemo/radiotherapy conditioning to  morbidity and mortality • Conditioning is sufficiently ‘immunosuppressive’ to allow engraftment of donor cells • Engrafted donor cells mediate the therapeutic ‘graft vs tumor’ effect

  11. NST + Autologous SCT for Multiple Myeloma(Maloney et al ASH, 2001) • n=41 median age 52 y (29 - 71) • Stage II (27%) or III (73%), 90% previous VAD chemo • Cy + G-CSF BPC mobilization and collection ~30d • autologous SCT with melphalan 200 mg/m2 40 - 120d • sibling NST with 200 cGY TBI (MMF + CSA GVH prophylaxistaper 80 - 180 d)

  12. NST + Auto SCT for Myeloma (cont) • Full chimerism by 1 - 2 mos without DLI • GVHD - 46% grade II - IV acute - 45% chronic • TRM at 1 yr - 12% (6 pts, 3 with GVHD) Disease Status Study Entry Post NST • CR - 6 6 - CR • PR - 15 9 - CR 5 - PR 1 - SD • Relapsed/refractory - 20 10 - CR 6 - PR 1 - SD 2 - PD

  13. NST Initial Results • Engraftment - donor chimerism can be achieved in >90% of patients with various conditioning regimens • Toxicity- TRM of ~ 20% in most series • acute and chronic GVHD and opportunistic infections seen with myeloablative conditioning still occur • Efficacy -longer follow-up, larger patient numbers, randomized trials required

  14. HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic GVL(Bonini et al. Science 276:1719. 1997) • HSV-TK (herpes simplex virus-thymidine kinase) gene expression renders cells susceptible to killing by ganciclovir • retroviral transduction of HSV-TK into DLI • DLI to treat relapse of CML (3), AML (3) or CmML (1), or EBV-LPD (2) post allo SCT

  15. HSV-TK Gene Transfer (cont) • 5/8 patients show tumor regression (3 CR) • 3 pts developing GVHD are treated with ganciclovir - 2 CR of acute GVH - 1 PR of chronic GVH • HSV-TK-transduced cells disappear as GVH regresses

  16. ganciclovir Bonini et al. Science 276:1719, 1997

  17. Hematopoietic Specific Minor Histocompatibility Ag (mHags) as Targets for Immunotherapy • mHags - peptides from polymorphic proteins, expressed on the plasma membrane and recognized by allo-MHC-restricted T cells • certain mHags have restricted expression on hematopoietic cells • effective lysis of leukemia cells and progenitors by mHag-specific CTLs

  18. From Mutis and Goulmy. Sem in Hematol 39:23, 2002

  19. Cellular Immunotherapy Strategies Using mHags HA-1/HA-2 • Immunotherapy of leukemic relapse with self-restricted mHag-specific CTLS after allo-SCT • vaccination of SCT donors with autologous dendritic cells pulsed with mHag peptides or transduced with mHag cDNA • use CTLs as a ‘booster’ in recipient after SCT

  20. Haploidentical SCT(Second European Workshop 12 - 14 Oct., 2000, Perugia, Italy) • ‘All’ patients will have a family donor • barriers include - graft rejection and GVHD • aggressive T-cell depletion (< 2 X 104 CD3+ c/kg)   GVHD •  CD34+ c dose (>5 X 106 c/kg) rejection • Pt conditioned with TBI + fludarabine, thiotepa, ATG • no GVHD prophylaxis

  21. Alloreactive NK cell killing Tumor Cell NK cell MHC recognized- NK function inhibited MHC NOT recognized - NK cell activated, tumor cell lysed

  22. Donor NK Cell Alloreactivity in Mismatched SCT(Ruggeri et al Science 295:2097)

  23. Conclusions • Donor alloreactivity can be harnessed for anti-tumor efficacy • Separating GVL from GVH for clinical SCT protocols remains challenging • Current progress in identifying and isolating effector cells and target antigens should soon allow the GVL effect to benefit more patients

More Related